Lonza has been building the science to support its ResistAid product, which is derived from larch bark. A pilot study published in the Nutrition Journal (Udani et al., 2010, 9:32) suggested that the larch bark extract may enhance the body’s response to a pneumonia vaccine.
This was followed by a2013 study published in Current Medical Research and Opinion (Vol. 29, pp. 251-258) which found that ResistAid supplements were associated with a 23% reduction in cold episodes, compared to placebo.
The study also found those who suffered no cold incidents was higher in the study group (91.2%) compared to the placebo group (88.5%).
The study conducted by German consultancy, analyze & realize, featured 199 healthy adults aged 18-70 who reported at least three colds in the previous six months.